Gekkowolf, I agree with everything you're saying. This is company whose primary product has always struggled to be anything other then a disappointment, the recent trial failure now puts this beyond doubt. The notion of ACW somehow pivoting to become a class leader in the anti-depressant market is at best fanciful as is the thought of a big BP swooping in to save it. It will likely trundle along at somewhere near it's current SP before running out of cash and ideas at which point it will enter the death spiral. I'll hold on to my modest holding as a tangible reminder to myself that speculating on companies that are poorly run and without focus is a foolish endeavor.
Could've, should've, didn't.
Lumpymash
ACW Price at posting:
2.5¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)